MCID: 48X005
MIFTS: 41

48,xyyy

Categories: Fetal diseases, Mental diseases, Neuronal diseases, Oral diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for 48,xyyy

Summaries for 48,xyyy

GARD: 19 A rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability, large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males.

MalaCards based summary: 48,xyyy, also known as 48,xyyy syndrome, is related to 49,xyyyy syndrome and down syndrome. The drugs Chlorhexidine and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, spinal cord and lung, and related phenotypes are high palate and short neck

Orphanet: 58 A rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability, large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males.

Wikipedia: 75 XYYY syndrome, also known as 48,XYYY, is a chromosomal disorder in which a male has two extra copies of... more...

Related Diseases for 48,xyyy

Diseases related to 48,xyyy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 16)
# Related Disease Score Top Affiliating Genes
1 49,xyyyy syndrome 11.2
2 down syndrome 10.4
3 47 xxx syndrome 10.4
4 radioulnar synostosis, nonsyndromic 10.2
5 hypogonadotropic hypogonadism 10.2
6 turner syndrome 10.2
7 aortic valve disease 1 10.1
8 coarctation of aorta 10.1
9 contractural arachnodactyly, congenital 10.1
10 cryptorchidism, unilateral or bilateral 10.1
11 aortic valve disease 2 10.1
12 aortic valve disease 3 10.1
13 hypospadias 10.1
14 synostosis 10.1
15 radioulnar synostosis 10.1
16 49, xxxxy syndrome 10.1

Graphical network of the top 20 diseases related to 48,xyyy:



Diseases related to 48,xyyy

Symptoms & Phenotypes for 48,xyyy

Human phenotypes related to 48,xyyy:

58 30 (show all 32)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 high palate 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000218
2 short neck 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000470
3 global developmental delay 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001263
4 depressed nasal bridge 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0005280
5 hypertelorism 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000316
6 delayed speech and language development 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000750
7 pes planus 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001763
8 intellectual disability, mild 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001256
9 thick lower lip vermilion 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000179
10 recurrent upper respiratory tract infections 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002788
11 acne 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001061
12 abnormal dermatoglyphics 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0007477
13 epicanthus 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000286
14 asthma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002099
15 azoospermia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000027
16 long philtrum 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000343
17 radioulnar synostosis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002974
18 tall stature 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000098
19 feeding difficulties 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0011968
20 dislocated radial head 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003083
21 aggressive behavior 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000718
22 abnormal renal morphology 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012210
23 low frustration tolerance 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000744
24 male hypogonadism 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000026
25 impulsivity 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100710
26 primary gonadal insufficiency 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0008193
27 irregularly spaced teeth 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0006316
28 enamel hypoplasia 30 Hallmark (90%) HP:0006297
29 intellectual disability 58 Very frequent (99-80%)
30 behavioral abnormality 58 Very frequent (99-80%)
31 abnormality of the foot 58 Very frequent (99-80%)
32 hypoplasia of dental enamel 58 Very frequent (99-80%)

Drugs & Therapeutics for 48,xyyy

Drugs for 48,xyyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 384)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
2
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
3
Cobicistat Approved Phase 4 1004316-88-4 24950485 25151504
4
Rilpivirine Approved Phase 4 500287-72-9 6451164
5
Elvitegravir Approved Phase 4 697761-98-1 23083982 5277135
6
Amantadine Approved Phase 4 768-94-5 2130
7
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
8
Rifabutin Approved, Investigational Phase 4 72559-06-9 46783538 6323490
9
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
10
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
11
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
12
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
13
Abacavir Approved, Investigational Phase 4 136470-78-5, 188062-50-2 441300
14
Zidovudine Approved Phase 4 30516-87-1 35370
15
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
16
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
17
Nevirapine Approved Phase 4 129618-40-2 4463
18
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
19
Cefuroxime Approved Phase 4 55268-75-2 5479529
20
Cefazolin Approved Phase 4 25953-19-9 33255
21
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
22
Insulin aspart Approved Phase 4 116094-23-6 16132418
23
Insulin lispro Approved Phase 4 133107-64-9 16132438
24
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
25
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
26
Acetaminophen Approved Phase 4 103-90-2 1983
27
Etravirine Approved Phase 4 269055-15-4 193962
28
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
29
Glimepiride Approved Phase 4 93479-97-1 3476
30
Saxagliptin Approved Phase 4 361442-04-8 11243969
31
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521 16682734
32
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
33
Nelfinavir Approved Phase 4 159989-64-7 64143
34
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
35
Indinavir Approved Phase 4 150378-17-9 5362440
36
Didanosine Approved Phase 4 69655-05-6 50599
37
Atorvastatin Approved Phase 4 134523-00-5 60823
38
Omalizumab Approved, Investigational Phase 4 242138-07-4
39
Interferon alfacon-1 Approved, Investigational Phase 4 118390-30-0
40
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
41
Hydroxyurea Approved Phase 4 127-07-1 3657
42
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
43
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
44
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
45
Orphenadrine Approved Phase 4 83-98-7 4601
46
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294
47
Framycetin Approved, Experimental, Vet_approved Phase 4 1404-04-2, 119-04-0, 3947-65-7 413349 8378
48
Fluocinolone acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
49
Pamidronic acid Approved Phase 4 40391-99-9 4674
50
Golimumab Approved Phase 4 476181-74-5

Interventional clinical trials:

(show top 50) (show all 336)
# Name Status NCT ID Phase Drugs
1 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
2 Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit. Unknown status NCT01883596 Phase 4 0.12% chlorhexidine solution;Placebo
3 An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
4 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
5 Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen. Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
6 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
7 Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks Unknown status NCT02470650 Phase 4 elvitegravir/cobicistat/emtricitabine/tenofovir;Darunavir;abacavir/lamivudine;Ritonavir;Lamivudine;rilpivirine
8 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
9 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin
10 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
11 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
12 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
13 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
14 Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720) Completed NCT02720107 Phase 4 fingolimod
15 A Phase IV, Prospective, Multicenter , Randomized Open Label, 48 Weeks Study to Evaluate the Antiretroviral Efficacy and Safety of Atazanavir or Darunavir,Each in Combination With a Fixed Dose of Tenofovir Emtricitabine in HIV-1-infected Treatment-naïve Subjects With CD4counts Below 200 µL. Completed NCT01928407 Phase 4 DARUNAVIR;ATAZANAVIR
16 24 Versus 48 Hours of First Generation or Second Generation Cephalosporin as Prophylaxis to Reduce Surgical Site Infection in Adult Cardiac Surgery Patients: a Randomized Controlled Trial Completed NCT04303390 Phase 4 Cefuroxime;Cefazolin
17 A Comparison of the Efficacy Beyond 48 Hours of Insulin Aspart (Novolog) and Lispro (Humalog) in Insulin Pumps Completed NCT00461331 Phase 4 Insulin Aspart;Insulin Lispro
18 Randomized, Multi-Center, Phase IV, Comparative Study to Assess the Efficacy and Safety of Combined Peg-Interferon Alpha-2a (40 kD) With Ribavirin Combined Therapy for 48 or 72 Weeks of Treatment and 24 Weeks of Follow-Up in Patients With Chronic Hepatitis C, Genotype 1, Co-Infected With Human Immunodeficiency Virus Completed NCT02761629 Phase 4 Peg-Interferon Alpha-2A;Ribavirin
19 An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy Completed NCT02068365 Phase 4 Pegyinterferon-alfa-2a
20 A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Tenofovir Disoproxil Fumarate And Emtricitabine As A First-line Regimen. Completed NCT00389402 Phase 4 saquinavir/ritonavir;atazanavir/ritonavir
21 A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function Completed NCT00641082 Phase 4 Clevudine;Adefovir dipivoxil
22 Efficacy and Safety of Saxagliptin and Glimepiride in Chinese Patients With Type 2 Diabetes Controlled Inadequately With Metformin Monotherapy (SPECIFY Study) : a 48-week, Multi-center, Randomized, Open-label Trial Completed NCT02280486 Phase 4 Saxagliptin;Glimepiride
23 Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan Completed NCT00495131 Phase 4 Pegylated interferon alfa-2a plus ribavirin
24 A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults With First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens Versus Pro-actively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy. Completed NCT00389194 Phase 4 continuing AZT+3TC or switching AZT+3TC to TDF+ FTC
25 Multicenter, Prospective, Comparative, Randomized Controlled Clinical Trial to Evaluate the Performance and the Safety of Promelaxin® Micro-enemas Vs. Macrogol 4000 Per os in the Treatment of Functional Chronic Constipation in Children Aged Between 6 and 48 Months. Completed NCT02751411 Phase 4 Macrogol 4000
26 A 48-week Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With Compensated Chronic Hepatitis B Completed NCT00441974 Phase 4 adefovir dipivoxil
27 Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time Completed NCT00192660 Phase 4 Lamivudine;Stavudine;Didanosine;Zidovudine;Tenofovir;Abacavir;Efavirenz (EFV);Nevirapine;Indinavir;Saquinavir;Amprenavir;Ritonavir;Nelfinavir;Tipranavir;enfuvirtide (T20)
28 XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria Completed NCT02392624 Phase 4 Omalizumab;Placebo
29 Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9: a Phase IV, Randomized, Open-labeled, Multicenter Trial Comparing 24-week vs. 48-week Therapy Completed NCT00575224 Phase 4 Pegylated interferon and ribavirin
30 A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (Abacavir 300mg, Lamivudine 150mg, and Zidovudine 300mg) BID vs Combivir (Lamivudine 150mg and Zidovudine 300mg) BID Plus Atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects Over 48 Weeks Completed NCT00082394 Phase 4 Trizivir;atazanavir;Combivir
31 A Phase IV 48-Week, Randomized, Open-Label, Multicenter Trial of Abacavir (300mg BID)/Efavirenz (600mg QD)/Didanosine (400mg QD) +/- Hydroxyurea (500mg BID) in HIV-1 Infected Subjects Failing Initial Therapy With 3TC/ZDV (or d4T) +/- Protease Inhibitor(s) Completed NCT00005018 Phase 4 Hydroxyurea;Abacavir sulfate;Efavirenz;Didanosine
32 A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol) Completed NCT00038506 Phase 4 abacavir/lamivudine/zidovudine;tenofovir
33 A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age Completed NCT03143101 Phase 4
34 A Phase IV 48 Week, Open Label, Pilot Study of Kaletra and Intelence Tablets in Naive Subjects Completed NCT01045369 Phase 4 Kaletra and Intelence Tablets
35 AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin. Completed NCT00241605 Phase 4 rosiglitazone/metformin
36 Does a Single Oral Dose of Dexamethasone After Successful Emergency Treatment of Migraine Reduce the Incidence or Severity of Rebound Headache Within 48 Hours? Completed NCT00216736 Phase 4 Dexamethasone;placebo
37 A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy Completed NCT00266318 Phase 4 Interferon Alfacon-1 and Ribavirin
38 Timing of IUI 24 or 48 Hours After Spontaneous LH Peak: a Randomised Controlled Trial Completed NCT01622023 Phase 4
39 Phase 2 Randomized Multicenter Controlled Study of Ribavirin Pre-treatment (8 Weeks) Followed by Standard Therapy With Ribavirin and Pegylated Interferon (48 Weeks) in Transplanted Patients With Recurrence of Chronic Hepatitis C Completed NCT00993122 Phase 4 ribavirin pre-treatment
40 48 Week Pilot Trial Assessing the Efficacy of Pioglitazone, Atorvastatin, Pegasys and Weight Based Ribavirin in Chronic Hepatitis C, Genotype 1 Patients Who Have Previously Relapsed or Did Not Respond to PegInterferon /Ribavirin Therapy Completed NCT00926614 Phase 4 pioglitazone (Actos);atorvastatin (Lipitor)
41 Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee Arthroplasty (TKA). Prospective, Randomized, Open-label Trial to Determine if Switching From Oral to Intravenous Acetaminophen and Orphenadrine for 48 Hours After TKA Improves Outcomes. Completed NCT02449369 Phase 4 Preop acetaminophen IV;Preop orphenadrine IV;Postop oral oxycodone & acetaminophen;Postop hydromorphone IV;Postop oral orphenadrine;Postop oral oxycodone;Postop acetaminophen IV;Postop orphenadrine IV
42 A Randomized, Open Labeled, Active-Controlled Trial of 24-Week Versus 48-Week Courses of Peg-Interferon Alpha Plus Ribavirin for Genotype-1 Infected Chronic Hepatitis C Patients Completed NCT00629967 Phase 4 pegylated interferon alpha 2a and ribavirin;Pegylated interferon alfa-2a and ribavirin
43 Effect of Early 48-hour Sevoflurane Inhalation on Gas Exchange and Inflammation in Patients Presenting With Acute Respiratory Distress Syndrome (ARDS) : a Monocentric, Prospective, Randomized Study. Completed NCT02166853 Phase 4 sevoflurane;midazolam
44 A Modified 48 Hour Patch Test of Neo-Synalar Cream, Sodium Lauryl Sulfate (Positive Control) and Saline (Negative Control) Completed NCT02168478 Phase 4 Neo-Synalar Cream
45 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
46 A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium. Completed NCT01573572 Phase 4 pegaptanib sodium injection
47 Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy Instead of a Triple Therapy That Includes Lopinavir/Ritonavir and Lamivudine or Emtricitabine in HIV Patients With Viral Suppression: Controlled Clinical Trial, Open Label, Randomized, of 48 Weeks of Follow-up Completed NCT01471821 Phase 4 antiretroviral treatment
48 A Randomized Controlled Study Compares the 48 Weeks Results of HIV-1 RNA Between Ritonavir-boosted Lopinavir Monotherapy and Ritonavir-boosted Lopinavir + Optimized Background Regimens in HIV-1 Infected Patients Who Have HIV-1 RNA <50 Copies/ml More Than 6 Months While Receiving Salvage PI-based Regimen and Previously Failed NNRTI-based Regimen Completed NCT01189695 Phase 4 Ritonavir-boosted lopinavir;optimized background regimens (OBRs)
49 A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401. Completed NCT01775137 Phase 4 TBM100
50 A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a (Pegasys®) Versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB) Completed NCT01277601 Phase 4 TDF;Peg-IFN

Search NIH Clinical Center for 48,xyyy

Genetic Tests for 48,xyyy

Anatomical Context for 48,xyyy

Organs/tissues related to 48,xyyy:

MalaCards : Liver, Spinal Cord, Lung, Heart, Prostate, Bone Marrow, Bone

Publications for 48,xyyy

Articles related to 48,xyyy:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Hypoventilation in the PACU is associated with hypoventilation in the surgical ward: Post-hoc analysis of a randomized clinical trial. 62
36370589 2023
2
Effects of a single dose of long-acting FSH on testicular blood flow, testicular echotexture, and circulating testosterone, estradiol, and nitric oxide in rams during the non-breeding season. 62
36219897 2023
3
Associations between pituitary-ovarian hormones and cognition in recently menopausal women independent of type of hormone therapy. 62
36395695 2023
4
Oil fly ash as a promise larvicide against the Aedes aegypti mosquitoes. 62
36341780 2023
5
Highly efficient in-situ cleaner degradation of difenoconazole by two novel dominant strains: Microflora diversity, monoclonal isolation, growth factor optimization, intermediates, and pathways. 62
36244419 2023
6
Influence of microplastics on the toxicity of chlorpyrifos and mercury on the marine microalgae Rhodomonas lens. 62
36273570 2023
7
Corrigendum to ArtifactID: Identifying artifacts in low-field MRI of the brain using deep learning Magnetic Resonance Imaging Volume 89, June 2022, Pages 42-48. 62
35396147 2023
8
Corrigendum to "A study of MRI gradient echo signals from discrete magnetic particles with considerations of several parameters in simulations" [Magn. Reson. Imaging, 48, May 2018, 129-137]. 62
30826151 2023
9
Comparison of carbapenem minimum inhibitory concentrations of Oxacillin-48-like Klebsiella pneumoniae by Sensititre, Vitek 2, MicroScan, and Etest. 62
35811020 2022
10
Reducing 48-h emergency department revisits and subsequent admissions: a retrospective study of increased emergency medicine resident floor coverage. 62
36474146 2022
11
Gastrointestinal colonization by OXA-48-producing Enterobacterales: risk factors for persistent carriage. 62
36205803 2022
12
Corrigendum to "Molecular basis of bacterial disinfectant resistance" [Drug Resist. Updates 48 (2020) 100672]. 62
36252361 2022
13
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting. 62
35758043 2022
14
Correction to Lancet HIV 2022; 9: e438-48. 62
35659003 2022
15
Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis. 62
35960887 2022
16
Ambulatory central BP and arterial stiffness in patients with and without intradialytic hypertension. 62
35986597 2022
17
Bilateral lysis of aortic saddle thrombus with early tissue plasminogen activator (BLASTT): a prospective, randomized, placebo-controlled study in feline acute aortic thromboembolism. 62
36350753 2022
18
Impact of the Timing of Endoscopic Retrograde Cholangiopancreatography for the Treatment of Acute Cholangitis: A Meta-analysis and Systematic Review. 62
36223305 2022
19
Personalized health risk assessment based on single-cell RNA sequencing analysis of a male with 45, X/48, XYYY karyotype. 62
36460769 2022
20
Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication. 62
35000515 2022
21
Nosocomial meningitis caused by ESBL- and OXA-48-producing Klebsiella pneumoniae and treated with ceftazidime-avibactam. Report of one case and review of the literature. 62
36183238 2022
22
Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital. 62
33980104 2022
23
Infant nutrition (donor human milk vs. maternal milk) and long-term neurodevelopmental and growth outcomes in very low birth weight infants. 62
35703947 2022
24
Cytotoxicity and anti-biofilm properties of novel hybrid-glass-based caries infiltrant. 62
36437129 2022
25
Speech and language development and genotype-phenotype correlation in 49 individuals with KAT6A syndrome. 62
35892268 2022
26
Comparison of Pregnancy Outcomes of Previable and Periviable Rupture of Membranes After Laser Photocoagulation for Twin-Twin Transfusion Syndrome. 62
36357989 2022
27
Comparison of Femoral Nerve Catheter, Adductor Canal Catheter, and Periarticular Liposomal Bupivacaine Infiltration for Postoperative Analgesia after Primary Total Knee Arthroplasty. 62
36470364 2022
28
Comparison of Ketamine, Dexmedetomidine and Lidocaine in Multimodal Analgesia Management Following Sleeve Gastrectomy Surgery: A Randomized Double-Blind Trial. 62
35382963 2022
29
Efficacy of Electroacupuncture Combined with Intravenous Patient-controlled Analgesia after Cesarean Section: A Randomized Clinical Trial. 62
36464237 2022
30
Efficacy of postoperative analgesia with duloxetine in posthemorrhoidectomy pain: a prospective, randomized, double-blind and placebo-controlled trial. 62
36457090 2022
31
Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia. 62
33771091 2022
32
Association between heme oxygenase one and sepsis development in patients with moderate-to-critical COVID-19: a single-center, retrospective observational study. 62
36464717 2022
33
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. 62
35973578 2022
34
The minimal invasive surfactant therapy: experience from a low resource setting. 62
33491516 2022
35
The complex lipid, SPPCT-800, reduces lung damage, improves pulmonary function and decreases pro-inflammatory cytokines in the murine LPS-induced acute respiratory distress syndrome (ARDS) model. 62
35786152 2022
36
A New Risk Score to Predict Intensive Care Unit Admission for Patients with Acute Pancreatitis 48 Hours After Admission: Multicenter Study. 62
36462125 2022
37
WD repeat domain 48 promotes hepatocellular carcinoma progression by stabilizing c-Myc. 62
36403194 2022
38
Detection and Characterization of Paraproteinemia in Canine Chronic B-cell Lymphocytic Leukemia Using Routine and Free Light Chain Immunofixation. 62
35883213 2022
39
Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial. 62
36136232 2022
40
Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study. 62
36472791 2022
41
Analgesia Effect of Ultrasound-Guided Transversus Abdominis Plane Block Combined with Intravenous Analgesia After Cesarean Section: A Double-Blind Controlled Trial. 62
35980557 2022
42
Klebsiella Species and Enterobacter cloacae Isolates Harboring blaOXA-181 and blaOXA-48: Resistome, Fitness Cost, and Plasmid Stability. 62
36453894 2022
43
Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial. 62
35973787 2022
44
Durable biochemical response and safety with oral octreotide capsules in acromegaly. 62
36173649 2022
45
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. 62
36183738 2022
46
Haemophilia A and B - evaluation of the Swedish prophylactic regimen by magnetic resonance imaging. 62
36469433 2022
47
Shoulder-Touch test to reveal incongruencies in persons with functional motor disorders. 62
36038356 2022
48
Modulating the lipid profile of blastocyst cell membrane with DPPC multilamellar vesicles. 62
35713365 2022
49
A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History. 62
35787693 2022
50
Association between early, small creatinine elevation and severe acute kidney injury in critically ill adult patients. 62
36084379 2022

Variations for 48,xyyy

Expression for 48,xyyy

Search GEO for disease gene expression data for 48,xyyy.

Pathways for 48,xyyy

GO Terms for 48,xyyy

Sources for 48,xyyy

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....